Catherine Chapon
Overview
Explore the profile of Catherine Chapon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
776
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Huvelle S, Pinon A, Coulon C, Bonasera T, Chapon C, Naninck T, et al.
ACS Omega
. 2024 Oct;
9(40):41732-41741.
PMID: 39398184
Positron emission tomography imaging using radiolabeled dolutegravir (DTG) is an interesting approach to understand the biodistribution of this antiretroviral drug at HIV-1 sanctuary sites. In the course of clinical translation,...
2.
De Groof T, Lauwers Y, De Pauw T, Saxena M, Vincke C, Van Craenenbroeck J, et al.
Eur J Nucl Med Mol Imaging
. 2024 Sep;
52(1):193-207.
PMID: 39218831
Purpose: While immunotherapy has revolutionized the oncology field, variations in therapy responsiveness limit the broad applicability of these therapies. Diagnostic imaging of immune cell, and specifically CD8 T cell, dynamics...
3.
Lemdani K, Marlin R, Mayet C, Perkov V, Pascal Q, Ripoll M, et al.
NPJ Vaccines
. 2024 Jun;
9(1):113.
PMID: 38902327
The characterization of vaccine distribution to relevant tissues after in vivo administration is critical to understanding their mechanisms of action. Vaccines based on mRNA lipid nanoparticles (LNPs) are now being...
4.
Galhaut M, Lundberg U, Marlin R, Schlegl R, Seidel S, Bartuschka U, et al.
Commun Med (Lond)
. 2024 Apr;
4(1):62.
PMID: 38570605
Background: The fight against COVID-19 requires mass vaccination strategies, and vaccines inducing durable cross-protective responses are still needed. Inactivated vaccines have proven lasting efficacy against many pathogens and good safety...
5.
Marlin R, Desjardins D, Contreras V, Lingas G, Solas C, Roques P, et al.
Nat Commun
. 2022 Aug;
13(1):5108.
PMID: 36042198
The COVID-19 pandemic has exemplified that rigorous evaluation in large animal models is key for translation from promising in vitro results to successful clinical implementation. Among the drugs that have...
6.
Kahlaoui N, Naninck T, Le Grand R, Chapon C
EJNMMI Phys
. 2022 Mar;
9(1):22.
PMID: 35316846
Introduction: A Vereos PET/CT device was adapted to be compatible with the experimentation in large animals within BSL-3 environment. The aim of this study was to investigate the impact of...
7.
Naninck T, Kahlaoui N, Lemaitre J, Maisonnasse P, De Mori A, Pascal Q, et al.
iScience
. 2022 Mar;
25(4):104101.
PMID: 35313622
Non-human primates (NHPs) are particularly relevant as preclinical models for SARS-CoV-2 infection and nuclear imaging may represent a valuable tool for monitoring infection in this species. We investigated the benefit...
8.
Naninck T, Contreras V, Coutte L, Langlois S, Hebert-Ribon A, Pelletier M, et al.
Curr Res Microb Sci
. 2021 Nov;
2:100072.
PMID: 34841362
Background: The resurgence of whooping cough in many countries highlights the crucial need for a better understanding of the pathogenesis of respiratory infection by . Exposure of baboons to by...
9.
Maisonnasse P, Aldon Y, Marc A, Marlin R, Dereuddre-Bosquet N, Kuzmina N, et al.
Nat Commun
. 2021 Oct;
12(1):6097.
PMID: 34671037
Effective treatments against Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) are urgently needed. Monoclonal antibodies have shown promising results in patients. Here, we evaluate the in vivo prophylactic and therapeutic...
10.
Marlin R, Godot V, Cardinaud S, Galhaut M, Coleon S, Zurawski S, et al.
Nat Commun
. 2021 Sep;
12(1):5215.
PMID: 34471122
Achieving sufficient worldwide vaccination coverage against SARS-CoV-2 will require additional approaches to currently approved viral vector and mRNA vaccines. Subunit vaccines may have distinct advantages when immunizing vulnerable individuals, children...